This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.
Targeted Therapies in Advanced Non–Small Cell Lung Cancer
Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania
Knowledge of the molecular biology of tumors is rapidly evolving. As a result, new targets for treatments are increasing the arsenal for treating advanced non–small cell lung cancer. This activity provides an update on newer targeted treatment strategies, including rationale/target, mechanisms of action, potential toxicities, and symptom management of targeted therapies.
Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation
Management of Patients With Cytotoxic Chemotherapy
Management of Patients Treated With Immunotherapy
Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer
What is the role of EGFR mutations in patients with NSCLC?
What is T790m and describe its role in drug resistance?
What is ALK and how does it impact the treatment of NSCLC?
What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?
What should pharmacists know about combining treatment agents for patients with NSCLC?
Bone Marrow Biopsy Demonstration Video